Drug intelligence / Profile preview

BSCT

Development stage: Phase 1
Lead developer: Biosceptre
Modality: Antibody-Based Therapeutics
Administration: Topical

Overview

BSCT is an anti-nf-P2X7 drug, specifically a highly purified sheep IgG formulation, used in a 10% ointment for topical application. It is investigated for its safety and tolerability, particularly in conditions like basal cell carcinoma.

Other names: Anti-nf-P2X7Anti-nf-P-2X7Anti-nf-P 2X7

Targets

P2RX7 (P2X purinoceptor 7)

Beyond the preview

Go deeper on BSCT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSCT.

Explore the full profile